Bilimsel Makale Arama | NeuralCipher AI

Açık erişim

Function and dysfunction of leucine-rich repeat kinase 2 (LRRK2): Parkinson's disease and beyond.

Bae JR, Lee BD.

BMB Rep · 2015-05-01

DOI: 10.5483/bmbrep.2015.48.5.032PMID: 25703537

Europe PMC üzerinden doğrulanabilir bibliyografik kayıt.

Makale detayına git Kaynağa git ↗

Açık erişim

The Role of α-Synuclein and LRRK2 in Tau Phosphorylation.

Kawakami F, Ichikawa T.

Parkinsons Dis · 2015-04-21

DOI: 10.1155/2015/734746PMID: 25977830

Europe PMC üzerinden doğrulanabilir bibliyografik kayıt.

Makale detayına git Kaynağa git ↗

Kaynak kaydı

Identification of novel variants in LRRK2 gene in patients with Parkinson's disease in Serbian population.

Janković MZ, Kresojević ND, Dobričić VS, Marković VV, Petrović IN, Novaković IV, Kostić VS.

J Neurol Sci · 2015-04-12

DOI: 10.1016/j.jns.2015.04.002PMID: 25899316

Europe PMC üzerinden doğrulanabilir bibliyografik kayıt.

Makale detayına git Kaynağa git ↗

Açık erişim

A novel GTP-binding inhibitor, FX2149, attenuates LRRK2 toxicity in Parkinson's disease models.

Li T, He X, Thomas JM, Yang D, Zhong S, Xue F, Smith WW.

PLoS One · 2015-03-27

DOI: 10.1371/journal.pone.0122461PMID: 25816252

Europe PMC üzerinden doğrulanabilir bibliyografik kayıt.

Makale detayına git Kaynağa git ↗

Kaynak kaydı

Cognitive and behavioral symptoms in Parkinson's disease patients with the G2019S and R1441G mutations of the LRRK2 gene.

Somme JH, Molano Salazar A, Gonzalez A, Tijero B, Berganzo K, Lezcano E, Fernandez Martinez M, Zarranz JJ, Gómez-Esteban JC.

Parkinsonism Relat Disord · 2015-03-02

DOI: 10.1016/j.parkreldis.2015.02.019PMID: 25840672

Europe PMC üzerinden doğrulanabilir bibliyografik kayıt.

Makale detayına git Kaynağa git ↗

Açık erişim

Interaction between SNCA, LRRK2 and GAK increases susceptibility to Parkinson's disease in a Chinese population.

Yu WJ, Cheng L, Li NN, Wang L, Tan EK, Peng R.

eNeurologicalSci · 2015-03-01

DOI: 10.1016/j.ensci.2015.08.001PMID: 29479569

Europe PMC üzerinden doğrulanabilir bibliyografik kayıt.

Makale detayına git Kaynağa git ↗

Kaynak kaydı

Adenoviral-mediated expression of G2019S LRRK2 induces striatal pathology in a kinase-dependent manner in a rat model of Parkinson's disease.

Tsika E, Nguyen AP, Dusonchet J, Colin P, Schneider BL, Moore DJ.

Neurobiol Dis · 2015-02-28

DOI: 10.1016/j.nbd.2015.02.019PMID: 25731749

Europe PMC üzerinden doğrulanabilir bibliyografik kayıt.

Makale detayına git Kaynağa git ↗

Kaynak kaydı

Cognitive profile of LRRK2-related Parkinson's disease.

Srivatsal S, Cholerton B, Leverenz JB, Wszolek ZK, Uitti RJ, Dickson DW, Weintraub D, Trojanowski JQ, Van Deerlin VM, Quinn JF, Chung KA, Peterson AL, Factor SA, Wood-Siverio C, Goldman JG, Stebbins GT, Bernard B, Ritz B, Rausch R, Espay AJ, Revilla FJ, Devoto J, Rosenthal LS, Dawson TM, Albert MS, Mata IF, Hu SC, Montine KS, Johnson C, Montine TJ, Edwards KL, Zhang J, Zabetian CP.

Mov Disord · 2015-02-04

DOI: 10.1002/mds.26161PMID: 25650144

Europe PMC üzerinden doğrulanabilir bibliyografik kayıt.

Makale detayına git Kaynağa git ↗

Kaynak kaydı

Modeling LRRK2 Pathobiology in Parkinson's Disease: From Yeast to Rodents.

Daniel G, Moore DJ.

Curr Top Behav Neurosci · 2015-01-01

DOI: 10.1007/7854_2014_311PMID: 24850078

Europe PMC üzerinden doğrulanabilir bibliyografik kayıt.

Makale detayına git Kaynağa git ↗

Kaynak kaydı

Clinical correlations with Lewy body pathology in LRRK2-related Parkinson disease.

Kalia LV, Lang AE, Hazrati LN, Fujioka S, Wszolek ZK, Dickson DW, Ross OA, Van Deerlin VM, Trojanowski JQ, Hurtig HI, Alcalay RN, Marder KS, Clark LN, Gaig C, Tolosa E, Ruiz-Martínez J, Marti-Masso JF, Ferrer I, López de Munain A, Goldman SM, Schüle B, Langston JW, Aasly JO, Giordana MT, Bonifati V, Puschmann A, Canesi M, Pezzoli G, Maues De Paula A, Hasegawa K, Duyckaerts C, Brice A, Stoessl AJ, Marras C.

JAMA Neurol · 2015-01-01

DOI: 10.1001/jamaneurol.2014.2704PMID: 25401511

Europe PMC üzerinden doğrulanabilir bibliyografik kayıt.

Makale detayına git Kaynağa git ↗

Kaynak kaydı

Higher frequency of certain cancers in LRRK2 G2019S mutation carriers with Parkinson disease: a pooled analysis.

Agalliu I, San Luciano M, Mirelman A, Giladi N, Waro B, Aasly J, Inzelberg R, Hassin-Baer S, Friedman E, Ruiz-Martinez J, Marti-Masso JF, Orr-Urtreger A, Bressman S, Saunders-Pullman R.

JAMA Neurol · 2015-01-01

DOI: 10.1001/jamaneurol.2014.1973PMID: 25401981

Europe PMC üzerinden doğrulanabilir bibliyografik kayıt.

Makale detayına git Kaynağa git ↗

Kaynak kaydı

Inhibitors of leucine-rich repeat kinase 2 (LRRK2): progress and promise for the treatment of Parkinson's disease.

Gilligan PJ.

Curr Top Med Chem · 2015-01-01

DOI: 10.2174/156802661510150328223655PMID: 25832719

Europe PMC üzerinden doğrulanabilir bibliyografik kayıt.

Makale detayına git Kaynağa git ↗

Kayıtlar bilimsel kaynaklardan alınır. Bibliyografik kayıt sayısı, Türkçe çeviri veya editoryal onay sayısı değildir.

785 makale bulundu

Function and dysfunction of leucine-rich repeat kinase 2 (LRRK2): Parkinson's disease and beyond.

The Role of α-Synuclein and LRRK2 in Tau Phosphorylation.

Identification of novel variants in LRRK2 gene in patients with Parkinson's disease in Serbian population.

A novel GTP-binding inhibitor, FX2149, attenuates LRRK2 toxicity in Parkinson's disease models.

Cognitive and behavioral symptoms in Parkinson's disease patients with the G2019S and R1441G mutations of the LRRK2 gene.

Interaction between SNCA, LRRK2 and GAK increases susceptibility to Parkinson's disease in a Chinese population.

Adenoviral-mediated expression of G2019S LRRK2 induces striatal pathology in a kinase-dependent manner in a rat model of Parkinson's disease.

Cognitive profile of LRRK2-related Parkinson's disease.

Modeling LRRK2 Pathobiology in Parkinson's Disease: From Yeast to Rodents.

Clinical correlations with Lewy body pathology in LRRK2-related Parkinson disease.

Higher frequency of certain cancers in LRRK2 G2019S mutation carriers with Parkinson disease: a pooled analysis.

Inhibitors of leucine-rich repeat kinase 2 (LRRK2): progress and promise for the treatment of Parkinson's disease.

Filtreler